11 November 2026

ASX Announcement

Results of Annual General Meeting

Firebrick Pharma Limited (ASX: FRE) (the **Company** or **Firebrick**) advises it held its Annual General Meeting today, at 11.00am (AEDT).

The resolutions were voted in accordance with the Notice of Annual General Meeting previously advised to the Australian Securities Exchange with all resolutions being passed on a poll.

Resolution 3 (Approval of 7.1A Mandate) was passed by a sufficient majority as a special resolution.

Further information required by section 251AA(2) of the Corporations Act 2001 (Cth) is attached.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -

About Firebrick Pharma

Firebrick Pharma is developing and commercialising novel consumer health products based on povidone-iodine (PVP-I). Firebrick's first product, Nasodine® Nasal Spray (0.5% PVP-I), has been launched in the United States, Singapore, and Fiji, and is approved for marketing in Indonesia and the Philippines. In the United States, online sales of the nasal spray have been growing rapidly, and the Company recently announced plans for distribution to retail drugstores. Firebrick is building a portfolio of Nasodine® products and in 2026, added Nasodine Throat Spray and Nasodine Sinus Rinse, providing a comprehensive range of products for upper respiratory tract care.

For further information, visit firebrickpharma.com or nasodine-sg.com

Contacts:

Shareholder Company contact:
Kam Watson, Firebrick Pharma
investors@firebrickpharma.com

Results of Meeting

Firebrick Pharma Limited

Annual General Meeting

Wednesday, 11 November 2026

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
1 ADOPTION OF REMUNERATION REPORT	P	39,699,034 99.14%	82,014 0.20%	44,183	263,547 0.66%	39,998,716 99.80%	82,014 0.20%	44,183	-
2 ELECTION OF DIRECTOR – AL MOGHADDAM	P	102,964,504 99.73%	82,183 0.08%	51,851	194,547 0.19%	103,195,186 99.92%	82,183 0.08%	51,851	Carried
3 APPROVAL OF 7.1A MANDATE	P	102,872,376 99.66%	82,864 0.08%	71,598	266,247 0.26%	103,174,758 99.92%	82,864 0.08%	71,598	Carried
4 ISSUE OF DIRECTOR INCENTIVE OPTIONS TO PETER MOLLOY	P	70,603,241 99.17%	395,429 0.56%	44,851	193,547 0.27%	70,832,923 99.44%	395,429 0.56%	44,851	Carried
5 ISSUE OF DIRECTOR INCENTIVE OPTIONS TO STEPHEN GOODALL	P	71,510,968 99.18%	395,429 0.55%	44,851	193,547 0.27%	71,740,650 99.45%	395,429 0.55%	44,851	Carried
6 ISSUE OF DIRECTOR INCENTIVE OPTIONS TO RICK LEGLEITER	P	102,651,258 99.43%	395,429 0.38%	52,851	193,547 0.19%	102,880,940 99.62%	395,429 0.38%	52,851	Carried
7 ISSUE OF DIRECTOR INCENTIVE OPTIONS TO AL MOGHADDAM	P	102,651,258 99.43%	395,429 0.38%	52,851	193,547 0.19%	102,880,940 99.62%	395,429 0.38%	52,851	Carried
8 APPROVAL TO ISSUE AWARDS UNDER THE COMPANY'S EMPLOYEE SECURITIES INCENTIVE PLAN	P	39,405,951 98.40%	445,429 1.11%	43,851	193,547 0.48%	39,635,633 98.89%	445,429 1.11%	43,851	Carried
9 APPOINTMENT OF AUDITOR	P	102,967,538 99.69%	60,000 0.06%	2,000	263,547 0.26%	103,267,220 99.94%	60,000 0.06%	2,000	Carried